Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023

Publisher Name :
Date: 28-Nov-2014
No. of pages: 57

GlobalData has released its new PharmaPoint Drug Evaluation report, "Avastin (Colorectal Cancer) Forecast and Market Analysis to 2023". Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Avastin (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Avastin and Vectibix are not recommended.

Avastin was the first agent of a new class of drugs that targeted the angiogenesis pathway. The anti-angiogenic agent is a humanized monoclonal IgG1 that binds to vascular endothelial growth factor-A (VEGF-A), preventing the ligand from binding to the VEGF receptor. Inhibition of the VEGF pathway prevents endothelial cells from proliferating and forming the new bloods vessels that are required for the tumor to grow. The drug delivered as a monotherapy is not curative, and must be co-administered with a chemotherapy regimen.

Scope


  • Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

  • Detailed information on Avastin including product description, safety and efficacy profiles as well as a SWOT analysis.

  • Sales forecast for Avastin for the top eight countries from 2013 to 2023.

  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.


Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return

  • Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer

  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

  • Make more informed business decisions from insightful and in-depth analysis of Avastin performance

  • Obtain sales forecast for Avastin from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Avastin (Colorectal Cancer) - Forecast and Market Analysis to 2023

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Clinical Staging 14
3.3 Symptoms 16

4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Screening and Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.1.3 Clinical Practice 24

5 Competitive Assessment 31
5.1 Overview 31

6 Avastin (Bevacizumab) 33
6.1 Overview 33
6.2 Efficacy 35
6.3 Safety 35
6.4 SWOT Analysis 37
6.5 Forecast 37

7 Appendix 39
7.1 Bibliography 39
7.2 Abbreviations 45
7.3 Methodology 48
7.4 Forecasting Methodology 48
7.4.1 Diagnosed Colorectal Cancer Patients 48
7.4.2 Percent Drug-Treated Patients 49
7.4.3 General Pricing Assumptions 49
7.4.4 Average Body Weight and Surface Area Across the 8MM 50
7.4.5 Individual Drug Assumptions 50
7.4.6 Generic Erosion 51
7.5 Primary Research - KOLs Interviewed for this Report 52
7.6 Primary Research - Prescriber Survey 53
7.7 About the Authors 54
7.7.1 Analyst 54
7.7.2 Global Head of Healthcare 55
7.8 About GlobalData 56
7.9 Disclaimer 56

List of Tables

Table 1: TNM and Staging Classification System for CRC 15
Table 2: Symptoms of Colorectal Cancer 16
Table 3: Treatment Guidelines for CRC 21
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 22
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 23
Table 6: Leading Treatments for CRC, 2014 32
Table 7: Product Profile ? Avastin 34
Table 8: Avastin SWOT Analysis, 2014 37
Table 9: Global Sales Forecast ($m) for Avastin, 2013-2023 38
Table 10: Average Body Weight and Surface Area Across the 8MM 50
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 53

  • Global Circulating Tumor Cells Market Professional Survey Report 2018
    Published: 18-Apr-2018        Price: US 3500 Onwards        Pages: 110
    This report studies Circulating Tumor Cells in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2013 to 2018, and forecast to 2025. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Janssen - Qiagen(Adnagen) - Acousys Biodevices - ApoCell......
  • Global Melanoma Therapeutics Market Size, Status and Forecast 2025
    Published: 05-Apr-2018        Price: US 3300 Onwards        Pages: 98
    This report studies the global Melanoma Therapeutics market, analyzes and researches the Melanoma Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - AstraZeneca - Amgen, Inc. - F. Hoffmann-La Roche Ltd. - Bristol-Myers Squibb Company - Novartis AG - Merck & Co., Inc. - Daiichi Sankyo Company, Limited - AB Sciences ......
  • United States Circulating Tumor Cells Market Report 2018
    Published: 27-Mar-2018        Price: US 3800 Onwards        Pages: 110
    In this report, the United States Circulating Tumor Cells market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and......
  • Global Glioblastoma Multiforme Treatment Market Size, Status and Forecast 2025
    Published: 22-Mar-2018        Price: US 3300 Onwards        Pages: 90
    This report studies the global Glioblastoma Multiforme Treatment market, analyzes and researches the Glioblastoma Multiforme Treatment development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - AbbVie, Inc - Activartis GmbH - Agenus Inc - Arog Pharmaceuticals, Inc - Bristol-Myers Squibb Company - Cavion LLC - Celldex Therapeutics Inc - Cortice......
  • Global Bladder Cancer Therapeutics Market Size, Status and Forecast 2025
    Published: 21-Mar-2018        Price: US 3300 Onwards        Pages: 97
    This report studies the global Bladder Cancer Therapeutics market, analyzes and researches the Bladder Cancer Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Pfizer - F. Hoffman-La Roche - Eli Lilly - Bristol-Myers Squibb - Merck - Sanofi - AstraZeneca - Bedford Lab - Accord Healthcare Market segme......
  • Global Circulating Tumor Cells Market Research Report 2018
    Published: 16-Mar-2018        Price: US 2900 Onwards        Pages: 118
    In this report, the global Circulating Tumor Cells market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Circulating Tumor Cells in these regions, from 2013 to 2025 (forecast), covering - North America - Europe - Ch......
  • Global Circulating Tumor Cells Sales Market Report 2018
    Published: 14-Mar-2018        Price: US 4000 Onwards        Pages: 119
    In this report, the global Circulating Tumor Cells market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Circulating Tumor Cells for these regions, from 2013 to 2025 (forecast), covering - United States - China - Europe......
  • Global Kaposi Sarcoma Market Size, Status and Forecast 2025
    Published: 07-Mar-2018        Price: US 3300 Onwards        Pages: 91
    This report studies the global Kaposi Sarcoma market, analyzes and researches the Kaposi Sarcoma development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Merck - Pfizer - Johnson & Johnson - GlaxoSmithKline - Bristol-Myers Squibb - Eli Lilly Market segment by Regions/Countries, this report covers - United States - EU - ......
  • Global Melanoma Partnering 2012 to 2018
    Published: 01-Mar-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Melanoma Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understand......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs